The grant will fund the development of a NLRP3-specific Positron Emission Tomography tracer to allow non-invasive imaging of inflammasome-driven inflammation in the brain.
To enhance the accuracy and probability of success of a clinical trial in neurodegenerative disease, it is important to select suitable patients at the appropriate staging of the disease.
It is also essential to determine whether the biological target of interest is being engaged by the drug in the brain.
One approach to achieve this in the central nervous system is by using an NLRP3-specific tracer during a PET scan. The tracer could quickly, accurately and non-invasively produce images showing the drug binding to target inflammasomes in the brain.
The NLRP3 inflammasome is believed to drive chronic inflammation associated with the progression of many neurodegenerative diseases, including Parkinson's Disease.
The PET tracer will also help Inflazome to determine what doses are needed for patients in larger clinical trials in the future. The Principal Investigator on this project is Prof. Matthew Cooper, CEO and co-founder of Inflazome, who is assisted by Co-Investigator Dr David Miller, Head of Medicinal Chemistry.
Inflazome is developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the NLRP3 inflammasome, which is now understood to drive many chronic and acute inflammatory conditions.
The NLRP3 inflammasome was recently shown to be associated with the progression of Parkinson's Disease in humans and in non-clinical models, in research published on 31 October 2018 in Science Translational Medicine.
This innovative research was co-authored by Prof. Cooper with research teams at The University of Queensland, Australia, led by A/Prof. Trent Woodruff and funded by The Michael J. Fox Foundation for Parkinson's Research and the Shake It Up Australia Foundation.
Parkinson's disease is the second most common neurodegenerative disorder worldwide, affecting more than 10m people.
It is characterised by the loss of dopamine-producing neurons, accompanied by chronic inflammation in the brain.
Inflazome has identified drugs to stop the chronic cycle of inflammation in the brain. Research published in Science Translational Medicine on 31 October 2018 found that the tool compound MCC950, a potent inhibitor of the NLRP3 inflammasome, given orally once a day could stop neuroinflammation.
MCC950 arrested the effects of Parkinson's in several animal models of the disease, leading to reduced brain neuron loss and higher levels of dopamine.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference